The TestAVec 3Rs Service Offer
Pharma. Biotech. Academic institutions. Whatever your sector, if you use lentivirus or AAV vector gene delivery, the
TestAVec 3Rs service offer is
As an in vitro assessment of the human safety and efficacy of your vector, the ʰInGeTox platform has a wide range of features that were created to help you achieve a more cost-effective approach to boost confidence in your vector before you enter the clinic.
To empower our clients to do better, go faster, with less expense, TestAVec is continually building upon its technology, so stay in touch to learn about upgrades and discuss the future in gene therapy safety.
Our early research was funded by the National Centre for Refinement, Reduction and Replacement of animals in experiments (NC3Rs) and sponsored by GlaxoSmithKline and Novartis in response to the need to reduce bias from oversensitive predictions of gene therapy vector mediated cancer risk made in animals and cell lines. Your data will be generated using phenotypically accurate 3D cellular cultures of human tissues.
Tell me more
Drop us a line
Why not act now to find out how you can maximise the efficacy of your vector during discovery whilst reducing the risks of adverse effects during costly clinical trials?
Whether it’s a full human safety and efficacy profile you want, or standalone vector safety, efficacy or purity, we’ll help you achieve reliable results, fast.